30 closest matches · ranked by relevance
Adult Acute Lymphoblastic Leukemia in Remission · Adult Acute Myeloid Leukemia in Remission · Adult Acute Myeloid Leukemia With 11q23 (MLL) Abnormalities
Primary: Progression-free Survival (PFS) Distribution of Patients With HL, NHL, and MM for Each Disease-specific High-dose Therapy Regimen, Estimate Provided for 10-yr PFS…
Acute Myeloid Leukemia · Lymphoblastic Leukemia · Acute Leukemia
Primary: Number of Participants With Grade 4 TMI Toxicity — 0; 0; 0; 2 Participants
Lymphoma · Leukemia
Primary: Composite Success Rate — 100; 75; 84 Percentage of participants
Hematologic Malignancies
Primary: Number of Participants With Successful Bone Marrow Engraftment — 1; 15; 1 Participants
Solid Tumor
Primary: The Primary Objective of the Dose Finding Component is to Determine the Maximum Tolerated Dose (MTD) of HCW9218 — 1.2 mg/kg
Multiple Myeloma · Amyloidosis
Primary: Number of Participants Without Renal Allograft Rejection at 6 Months Post-transplant — 1 Participants
Advanced Malignant Solid Neoplasm · Recurrent Childhood Ependymoma · Recurrent Ewing Sarcoma
Primary: Objective Response Rate — 0 percentage of participants
Neoplasms · Lymphomas
Primary: Dose Limiting Toxicity (DLTs) — 0; 0; 0; 0 Toxicities
Adenocarcinoma · Neoplasms
Primary: Number of Participants With Adverse Events (AEs) and Serious Adverse Events (SAEs): Part 1 — 4; 5; 3; 7 participants
Lymphomas · Solid Tumors · NSCLC
Primary: Phase 2: Response Rate of This Combination in Participants With Colon Cancer, Non-small Cell Lung Cancer (NSCLC), and Granulosa Cell Ovarian Cancer — 0; 0; 0; 1…
Advanced Malignant Solid Neoplasm · Ann Arbor Stage III Hodgkin Lymphoma · Ann Arbor Stage III Non-Hodgkin Lymphoma
Primary: Objective Response Rate (ORR) — 5 Percentage of participants
Solid Tumor · Lymphoma · Peripheral T-Cell Lymphoma
Primary: Evaluate the Safety and Tolerability of ALRN-6924 in Adult Patients With Advanced Solid Tumors or Lymphomas With Wild-type (WT) TP53 Who Are Refractory to or Intolerant…
Myelodysplastic Syndrome · Multiple Myeloma · Hodgkin Lymphoma
Primary: Number of Participants Who Experienced One or More Adverse Events (AEs): — 27; 28; 31; 21 Participants
Acute Myelogenous Leukemia (AML) · Acute Lymphoblastic Leukemia (ALL) · Myelodysplastic Syndromes (MDS)
Primary: Number of Participants With Dose Limiting Toxicity (DLT) Events — 0; 0; 0; 0 Participants
Thrombocytopaenia
Primary: Number of Participants With Any Adverse Event (AE) or Serious Adverse Event (SAE): Pre-therapy, On-therapy + 30 Days and Post-therapy in Phase I — 3; 8; 4; 9 Participants
Hematologic Neoplasms
Primary: Number of Recipients Who Developed Grades I-IV Acute Graft Versus Host Disease (GVHD) Following a Combination of Cyclosporine and a Mini-dose Methotrexate Regimen for…
Recurrent B-Cell Childhood Acute Lymphoblastic Leukemia · Recurrent Childhood B-Lymphoblastic Lymphoma
Primary: 3-year Overall Survival Rate of Patients With Relapsed ALL — 94.4; 55.5; 72.63 percentage of participants — p=0.035
Neuroblastoma · Sarcoma · Rhabdomyosarcoma-Embryonal
Primary: Number of Participants With a Positive Immune Response as Evidenced by the Delayed Type of Hypersensitivity (DTH) Reaction Assay — 0; 15 Participants — p=0.043
Leukemia · Lymphoma
Primary: Number of Patients Who Received 2 Doses of Natural Killer (NK) Cell Infusions — 3; 2; 5 Participants
Hematologic Malignancies
Primary: Number of Participants With First Cycle Dose-limiting Toxicities (DLTs) — 0; 0; 0; 0 Participants
Small Cell Lung Cancer · Gastric Adenocarcinoma · Esophageal Adenocarcinoma
Primary: Clinical Benefit Rate (CBR) at 24 Weeks of PDR001+LAG525 by Tumor Type in Multiple Solid Tumors and Lymphoma — 25; 3; 2; 5 Participants
Leukemia, Acute Lymphocytic (ALL) · Leukemia, Myeloid, Acute(AML) · Leukemia, Myeloid, Chronic(CML)
Primary: Event-free Survival (EFS) — 54.8 Percentage of participants
Advanced/Metastatic Solid Malignancies
Primary: Overall Response Rate (Confirmed) — 1; 1 Participants
Multiple Myeloma · Non-Hodgkin Lymphoma · Hodgkin Disease
Primary: Number of Patients Who Achieved Mobilization Success of Hematopoietic Stem Cells in Patients With Multiple Myeloma (MM), Non-Hodgkin Lymphoma (NHL) or Hodgkin Disease…
B-Cell Acute Lymphoblastic Leukemia, Adult
Primary: Best Overall Response Rate (ORR) — 6; 0; 1; 0 Participants
Hematologic Malignancy
Primary: Overall Survival — 79; 49 Participants
Myelodysplastic Syndrome · Acute Myeloid Leukemia (AML) · Chronic Myeloid Leukemia (CML)
Primary: Cellular Immune Response — 4 participants
Advanced B-cell Lymphoid Malignancies
Primary: Total Number of Adverse Events. — 2 Adverse events
Acute Leukaemia · Chronic Disease · Leukemia
Primary: Number of High Risk Pediatric Patients With Successful Sustained Donor Engraftments — 16; 18; 10 participants
Neuroblastoma
Primary: Overall Response Rate [Complete Response + Very Good Partial Response + Partial Response (CR + VGPR + PR)] — 42 Participants